A Phase I Trial of ZIO-101 in Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: ZIO-101 (Darinaparsin)
- Registration Number
- NCT00591396
- Lead Sponsor
- Alaunos Therapeutics
- Brief Summary
A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm ZIO-101 (Darinaparsin) -
- Primary Outcome Measures
Name Time Method toxicities 6 months
- Secondary Outcome Measures
Name Time Method pharmacokinetics 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms and targets does Darinaparsin (ZIO-101) exploit in solid tumor therapy?
How does ZIO-101's efficacy compare to standard-of-care chemotherapies in Phase I solid tumor trials?
Which predictive biomarkers correlate with response to Darinaparsin in NCT00591396 solid tumor patients?
What adverse event profiles and management strategies were observed in ZIO-101 Phase I trials for solid tumors?
Are there combination therapies or alternative arsenic-based compounds showing synergy with ZIO-101 in solid tumor research?